الولايات المتحدة · وكالات وأخبار لحظية · Business Wire

Ropeg Gains ET Approvals in Major Global Markets as European Patients Await Access

نشره Business Wire · الولايات المتحدة منذ 13 س

PharmaEssentia’s blood cancer treatment, ropeginterferon alfa-2b (Ropeg), has secured approvals for essential thrombocythemia (ET) in Taiwan, Japan, the ...

اقرأ المقال كاملًا على Business Wire سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (www.businesswire.com)

يستحق القراءة أيضًا

PR Newswire

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lumentum Holdings Inc. (NASDAQ: LITE)

Associated Press (Business)

8 innovative gifts meant to change up how we drive, cook, sleep and more

Dow Jones Newswires

Rethinking AI in Enterprise Intelligence

MT Newswires

Ropeg Gains ET Approvals in Major Global Markets as European Patients Await Access

مشاركة

يستحق القراءة أيضًا

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lumentum Holdings Inc. (NASDAQ: LITE)

8 innovative gifts meant to change up how we drive, cook, sleep and more

Rethinking AI in Enterprise Intelligence

Global Financial News from MT Newswires Now Live in Microsoft Copilot